Healthcare · Biotechnology
Price
$0.95
Market Cap
$317,361
Employees
12
Beta
2.72
Avg Volume
1,404,453
CEO
David Allan White
Business Description
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.20
Stock Price: $0.95
EPS (Diluted): -4.73
EPS (Diluted): -4.73
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
16.24
Stock Price: $0.95
Total Equity: $15.76M
Shares: 3,281,915
Total Equity: $15.76M
Shares: 3,281,915
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-18.91
Market Cap: $317,361
Total Debt: $24,362
Cash: $5.22M
EBITDA: -$13.27M
Total Debt: $24,362
Cash: $5.22M
EBITDA: -$13.27M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$250.8M
Market Cap: $317,361
Total Debt: $24,362
Cash: $5.22M
Total Debt: $24,362
Cash: $5.22M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
313.95
Stock Price: $0.95
Revenue: $815,371
Shares: 3,281,915
Revenue: $815,371
Shares: 3,281,915
EV/Sales (Total value vs revenue — works when P/E can't)
API307.61
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
77.6%
Gross Profit: $632,913
Revenue: $815,371
Revenue: $815,371
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-778.2%
Operating Income: -$6.34M
Revenue: $815,371
Revenue: $815,371
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,721.0%
Net Income: -$14.03M
Revenue: $815,371
Revenue: $815,371
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-89.0%
Net Income: -$14.03M
Total Equity: $15.76M
Total Equity: $15.76M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-60.0%
Operating Income: -$6.34M
Tax Rate: 0.0%
Equity: $15.76M
Total Debt: $24,362
Cash: $5.22M
Tax Rate: 0.0%
Equity: $15.76M
Total Debt: $24,362
Cash: $5.22M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.66
Current Assets: $6.07M
Current Liabilities: $9.14M
Current Liabilities: $9.14M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $24,362
Total Debt: $24,362
Total Equity: $15.76M
Long-Term Debt: $24,362
Total Debt: $24,362
Total Equity: $15.76M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.25
Revenue: $815,371
Shares: 3,281,915
Shares: 3,281,915
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$4.80
Total Equity: $15.76M
Shares: 3,281,915
Shares: 3,281,915
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-2.95
Operating CF: -$9.68M
CapEx: $0.00
Shares: 3,281,915
CapEx: $0.00
Shares: 3,281,915
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.95
Stock Price: $0.95
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$14.03M
Net Income: -$14.03M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ONCO against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 5:39am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $58,465 | $2.5M | $815,371 |
| Cost of Revenue | $4,890 | $6,752 | $1.2M | $1.5M | $182,458 |
| Gross Profit | $-4,890 | $-6,752 | -$1.1M | $1.1M | $632,913 |
| Operating Expenses | $3.4M | $13.5M | $34.9M | $57.5M | $7.0M |
| Operating Income | -$3.4M | -$13.5M | -$36.0M | -$56.5M | -$6.3M |
| Net Income | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| EBITDA | -$3.4M | -$13.4M | -$36.7M | -$57.6M | -$13.3M |
| EPS | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 5:39am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $25.8M | $4.6M | $646,500 | $5.2M |
| Total Current Assets | $3.1M | $26.3M | $5.8M | $950,267 | $6.1M |
| Total Assets | $3.1M | $26.3M | $87.5M | $28.2M | $24.9M |
| Current Liabilities | $1.6M | $3.9M | $17.2M | $18.3M | $9.1M |
| Long-Term Debt | $0 | $0 | $118,857 | $0 | $24,362 |
| Total Liabilities | $1.6M | $3.9M | $86.1M | $18.6M | $9.2M |
| Total Equity | $1.4M | $22.4M | -$5.6M | $9.6M | $15.8M |
| Retained Earnings | -$6.0M | -$19.4M | -$56.8M | -$115.7M | -$131.2M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 5:39am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Capital Expenditure | $-1,924 | $-9,339 | $-55,044 | $-28,471 | $0 |
| Free Cash Flow | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-566,810 | $-58,981 | $-718 | $0 |
| Net Change in Cash | -$2.4M | $23.8M | -$21.2M | -$3.9M | $4.6M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 1:18pm (19h ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$800,000 $800,000 – $800,000
|
$815,371 $815,371 – $815,371
|
$881,218 $881,218 – $881,218
|
$952,384 $952,384 – $952,384
|
| EBITDA |
$-159,999 $-159,999 – $-159,999
|
$-163,074 $-163,074 – $-163,074
|
$-176,243 $-176,243 – $-176,243
|
$-190,476 $-190,476 – $-190,476
|
| Net Income |
-$474.2B -$474.2B – -$474.2B
|
-$552.3B -$552.3B – -$552.3B
|
-$658.4B -$658.4B – -$658.4B
|
-$703.0B -$703.0B – -$703.0B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 5:39am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | +4,217.3% | -67.7% |
| Gross Profit Growth | -38.1% | -16,593.8% | +193.6% | -40.0% |
| Operating Income Growth | -294.5% | -167.3% | -56.8% | +88.8% |
| Net Income Growth | -292.7% | -178.8% | -56.9% | +76.1% |
| EBITDA Growth | -293.1% | -173.7% | -56.9% | +77.0% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ONCO — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ONCO.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30